Monkeypox update: FDA focuses on testing as cases continue to rise

The U.S. Food and Drug Administration (FDA) has issued a new guidance offering recommendations for validating the accuracy and reliability of diagnostic tests designed to identify monkeypox. There have been more than 21,000 confirmed monkeypox cases in the United States as of Sept. 7.

The guidance also offers optional validation templates that developers can use when submitting an Emergency Use Authorization (EUA) request, or for their own internal validation purposes. 

“Today’s important actions further aid the monkeypox response by working toward expanding vital testing capacity and facilitating the detection of cases nationwide in an effort to stem the spread of the virus,” said Jeff Shuren, MD, JD, director of the FDA’s Center for Devices and Radiological Health, in the FDA's update. “The policy announced today is intended to support the development of more validated monkeypox tests and expand access to testing.”

The guidance also explains that, in order to address availability and accessibility concerns, the FDA temporarily “does not intend to enforce requirements” for certain laboratory-developed, appropriately validated tests without submission of an EUA—so long as the laboratories notify the FDA within 30 days. 

Additionally, the FDA issued the first EUA for an in-vitro monkeypox diagnostic test, the Quest Diagnostics Monkeypox Virus Qualitative Real-Time PCR

As the virus progresses, the FDA will continue to work with the public health community and update their guidance as necessary. 

Jessica Kania is a digital editor who has worked across the Innovate Healthcare brands, including Radiology Business, Health Imaging, AI in Healthcare and Cardiovascular Business. She also has vast experience working on custom content projects focused on technology innovation, clinical excellence, operational efficiency and improving financial performance in healthcare.  

Around the web

Given the precarious excitement of the moment—or is it exciting precarity?—policymakers and healthcare leaders must set directives guiding not only what to do with AI but also when to do it. 

The final list also included diabetes drugs sold by Boehringer Ingelheim and Merck. The first round of drug price negotiations reduced the Medicare prices for 10 popular drugs by up to 79%. 

HHS has thought through the ways AI can and should become an integral part of healthcare, human services and public health. Last Friday—possibly just days ahead of seating a new secretary—the agency released a detailed plan for getting there from here.